8-K filing — Spero Therapeutics, Inc. (SPRO)
Filed: 2026-08-12 AccNo: 0001193125-26-346855 Size: 210 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Spero Therapeutics Q2 EPS $(0.16) Down From $(0.03) YoY
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 8:01 PM
- Checked
- Aug 12, 2026, 8:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Spero Therapeutics shares are trading lower. The company announced an exclusive license agreement with Innovent Biologics for SP001, a third‑gen Fc‑silent anti‑CD40L antibody.
Read original at benzingaSpero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Spero Therapeutics and Innovent Biologics announced an exclusive license agreement for SP001 (IBI355), a third-generation anti-CD40L antibody. Spero receives global rights excluding Greater China, with potential milestone payments totaling approximately $1.1 billion plus tiered royalties. Spero plans to initiate a Phase 2 trial in IgG4-related disease in Q2 2027, while Innovent will pursue a Phase 2 trial in Sjögren's disease in China by early 2027.
Read original at globenewswire-inc